Kedrion Biopharma joins IPOPI in celebrating World PI Week 2017
Global campaign to improve early diagnosis and optimal treatments for PID
Kedrion Biopharma signs agreement with European Hemophilia Consortium (EHC)
The agreement aims to improve patient access to coagulation disorders treatments in Europe
Kedrion Biopharma initiatives for World Hemophilia Day 2017
The goal is to provide wider access to plasma-derived therapies for coagulation disorders the world over
New company AO Kirov Plasma established in Russia
It’s a joint venture between Kedrion Biopharma, Nacimbio and Pharmastandard
Article by Prof. Farrugia and Daniela Scaramuccia published on “Biologicals”
International medical journal hosts review of contract plasma fractionation dynamics
Kedrion Biopharma strengthens its presence in Russia
Memorandum of Understanding with Russian pharmaceutical companies for a joint plasma products manufacturing program
FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin
Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017
Hemophilia seen through children’s eyes: Kedrion teams up with LA Kelley
Three books of the series My First Factor Creation are now available for free download
Kedrion took part in the 17th ESID Meeting with 44 international guests
The conference focused on new insights into PIDs’ diagnosis and therapies
Pharmaceutical digitization: how to improve patient care and engagement
Kedrion Biopharma Advisor Prof. Albert Farrugia lectures at “The Future of Science” Conference in Venice, Italy